Telix supplies Bayer with Illuccix® for global phase III prostate therapy
Melbourne, Australia, May 7, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited TLX Telix, the Company) announced today that it has reached an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, Gallium Ga 68 Gozetotide Injection Preparation Kit)[1] for the phase III ARASTEP study (ClinicalTrials.gov identifier: NCT05794906). This global study evaluates the efficacy of Bayer’s androgen […]
Phase 2 Psilocybin Therapy Trial for Patients With Treatment-Resistant…
cannabis company Creso Pharma COPHF‘s wholly owned Psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early insights into its progress Phase 2 clinical study Evaluating the Efficacy of Psilocybin in Treatment-Resistant PTSD. The single-arm, open-lab study is testing the effectiveness of Halucenex synthetic psilocybin aqueous solution, Lucenex, in both 10 mg and 25 mg formats […]
Autolus Therapeutics Announces Pivotal Phase 2 FELIX Trial of…
LONDON, April 27, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc AUTHa clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, today announced that the summary of the pivotal Phase 2 FELIX study of obecabtagene-autoleucel (Obe-Cel) in relapsed/refractory ( r/r) adult B-cell acute lymphoblastic leukemia (ALL) has been selected for an oral presentation at the 2023 American […]
UNITY Biotechnology to Host Program Update on BEHOLD, Phase 2…
SOUTH SAN FRANCISCO, Calif., April 23, 2023 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) UBXa biotechnology company developing therapeutics to slow, halt or reverse the diseases of aging, announced today that on Monday, 24 am ET, it had partnered with retinal expert and Senior Clinical Advisor Robert B. Bhisitkul, MD, Ph.D. , the University of […]
Atai Brings R-Ketamine Through Phase 1 Bridging Study, Update And…
Clinical-stage biopharmaceutical company atai Life Sciences ATAI announced the dosing of the first subject in phase 1 of its intravenous to subcutaneous phase 1 subsidiary Perception Neuroscience bridge study from proprietary R-ketamine, PCN-101. The open-label study is designed to evaluate the safety, tolerability and pharmacokinetic profile of 60 mg, 90 mg and 120 mg of […]
AB Science announced the publication of the pivotal phase 3 study of masitinib…
PRESS RELEASE PUBLICATION OF MASITINIB ADJUSTABLE PHASE 3 CLINICAL STUDY IN ALZHEIMER’S DISEASE IN THE MAGAZINE ALZHEIMER RESEARCH & THERAPY Paris, 28 February, 2023, 8 o’clock CET AB Science S.A (Euronext – FR0010557264 – AB) today announced the publication of the results of its positive pivotal phase 3 study (AB09004) of masitinib in mild to […]
Celyad Oncology moves fully into the preclinical phase, pulls the plug…
Celyades Oncology CYAD offers an update on its Celyad 2.0 business strategy, which has been adopted and implemented in recent months. The company has assembled a fundamental and broad IP fortune. In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in the following areas: Multiplexing approach of the short hairpin […]
AltruBio presents new positive data from its completed Phase 1b study…
-Participants with SR-aGVHD disease achieved 67% ORR and 17% CR as measured by best response- -Participants with TR-aGVHD (11 of 12 concurrent with ruxolitinib) achieved 67% ORR and 25% CR at Day 28- -Median survival benefits in TR-aGVHD participants compared to historical controls favorableNeihulizumab was well tolerated, with safety profiles similar to those observed when […]
Phase Shifter Market Growth and Business Opportunities in the Coming…
TMR Research’s Phase Shifter Market report stands out because of the experience of TMR experts. The market study conducted by the team of analysts includes various aspects influencing the market growth such as competitive analysis, key trends, regional prospects, challenges, and new launches. Stakeholders get in-depth and accurate information on the state of the market […]
Acadia Trofinetide Phase III – Positive top-line clinical results
On 12/06/2021, US time, Acadia Pharmaceuticals (Nasdaq: ACAD) announced positive top-line results from its Phase III clinical trial of its drug candidate Trofinetide. The phase III study, called Lavender, will be used primarily to evaluate the safety and effectiveness of trofinetide in treating Rett Syndrome (RS). A total of 189 subjects were enrolled, all females […]